
FDA Approves Susvimo for Treatment of Diabetic Retinopathy
The US Food and Drug Administration (FDA) has approved Susvimo 100 mg/mL, a ranibizumab injection administered via the Port Delivery System (PDS), to treat diabetic retinopathy (DR).1 Announced by Genentech, a member of the Roche Group, on May 22, 2025 …